Valuation: Daxor Corporation

Market Cap 60.31M 52.95M 48.74M 45.42M 85.66M 5.73B 87.4M 586M 227M 2.81B 226M 222M 9.8B P/E 2026 *
-49.3x
P/E 2027 * -345x
Enterprise Value 60.31M 52.95M 48.74M 45.42M 85.66M 5.73B 87.4M 586M 227M 2.81B 226M 222M 9.8B EV / Sales 2026 *
5.07x
EV / Sales 2027 * 2.9x
Free-Float
47.22%
Yield 2026 *
-
Yield 2027 * -
1 day+0.54%
1 week-1.43%
Current month+0.54%
1 month+2.88%
3 months+7.48%
6 months-29.83%
Current year-29.83%
1 week 9.86
Extreme 9.86
10.61
1 month 9.26
Extreme 9.26
11.16
Current year 8.56
Extreme 8.56
14.75
1 year 8.56
Extreme 8.56
14.76
3 years 6.55
Extreme 6.55
14.76
5 years 6.55
Extreme 6.55
14.76
10 years 3.4
Extreme 3.4001
24.08
Manager TitleAgeSince
Chief Executive Officer 56 2012-12-31
Director of Finance/CFO 69 2018-09-27
Chief Tech/Sci/R&D Officer - 2024-06-04
Director TitleAgeSince
Director/Board Member 91 1988-12-31
Chairman 56 2017-02-13
Director/Board Member 70 2016-06-21
Date Insider Type Main position Quantity % Market Cap.
06-22Free

Director

2,500 0.0429%
06-22Free

Director

2,500 0.0429%
06-22Free

Chief Executive Officer

30,000 0.5148%
Change 5-day change 1-year change 3-year change Capi.($)
+0.54%-1.43%+7.25%+7.81% 60.31M
+0.66%+1.30%+19.00%+103.55% 14.46B
+0.05%+4.19%+54.25%+142.36% 12.1B
0.00%+0.58%-4.85%+31.90% 8.94B
+0.12%+1.95%-12.28%-10.83% 7.72B
+0.27%+2.62%+33.31%+123.86% 7.46B
-0.11%+0.35%+2.31%+56.04% 6.32B
-0.07%-1.11%+10.25%+19.58% 4.61B
-0.09%-0.37%+10.34%+2.86% 4.06B
+4.01%+3.02% - - 3.89B
Average +0.53%+0.83%+13.29%+53.02% 6.96B
Weighted average by Cap. +0.39%+1.15%+17.43%+73.06%

Financials

2026 *2027 *
Net sales 11.9M 10.45M 9.62M 8.96M 16.9M 1.13B 17.24M 116M 44.82M 555M 44.68M 43.71M 1.93B 20.8M 18.26M 16.81M 15.66M 29.54M 1.98B 30.14M 202M 78.33M 971M 78.1M 76.41M 3.38B
Net income -1.2M -1.05M -970K -904K -1.7M -114M -1.74M -11.66M -4.52M -56M -4.51M -4.41M -195M -200K -176K -162K -151K -284K -19.01M -290K -1.94M -753K -9.33M -751K -735K -32.48M
Net Debt - -
Logo Daxor Corporation
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Employees
45
Date Price Change Volume
26-07-01 US$10.35 +0.54% 1,238
26-06-30 US$10.29 +1.83% 7,849
26-06-29 US$10.11 +0.86% 3,006
26-06-26 US$10.02 -2.87% 1,854
26-06-25 US$10.32 -1.71% 550
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.35USD
Average target price
22.50USD
Spread / Average Target
+117.39%

Quarterly revenue - Rate of surprise